RESUMEN
U tubes have been used for a wide variety of hepatobiliary problems. We report a patient with multiple complications possibly related to the use of a U tube. These include secondary biliary cirrhosis, intrahepatic bilomas, and enterocutaneous fistula. The relatively rare entities of intrahepatic biloma and enterocutaneous fistula are reviewed.
Asunto(s)
Enfermedades de las Vías Biliares/etiología , Stents/efectos adversos , Anastomosis Quirúrgica , Bilis , Fístula Biliar/etiología , Fístula Cutánea/etiología , Humanos , Yeyunostomía , Cirrosis Hepática Biliar/etiología , Masculino , Persona de Mediana EdadRESUMEN
The aim of this study was to characterize the circadian variation of oral tacrolimus disposition in 8 stable liver allograft recipients. In the steady state, a total of 23 blood samples was taken before and after tacrolimus administration during a 24-hr period and the pharmacokinetic parameters were compared. The area under the curve (AUC) of tacrolimus after the morning dose was significantly larger than after the evening dose (211+/-43 ng x hr/ml [morning] vs. 179+/-45 ng x hr/ml [evening], P=0.02). The time to peak (Tmax) was significantly shorter after the morning dose than after the evening dose (1.6+/-0.7 hr [morning] vs. 2.9+/-0.6 hr [evening], P=0.002). The peak (Cmax) was significantly higher after the morning dose than after the evening dose (32.2+/-10.2 ng/ml [morning] vs. 19.1+/-4.3 ng/ml [evening], P=0.003). However, the trough (Cmin) was not significantly different between the morning dose and the evening dose (13.1+/-3.9 ng/ml [morning] vs. 13.3+/-4.4 ng/ml [evening], P=0.4). This study demonstrated that tacrolimus disposition in liver transplant patients was determined by administration time.
Asunto(s)
Ritmo Circadiano/fisiología , Trasplante de Hígado/fisiología , Tacrolimus/farmacocinética , Adulto , Femenino , Humanos , Enfermedades Renales/inducido químicamente , Masculino , Persona de Mediana Edad , Tacrolimus/efectos adversosRESUMEN
This study investigated the effect of grapefruit juice on cyclosporine A (CsA) bioavailability in 10 renal transplant patients. Under CsA steady state conditions, patients were randomly administered their usual dose of CsA with either 8 ounces of grapefruit juice or 8 ounces of water. Using a crossover design, a 12-hr pharmacokinetic study was then conducted. Grapefruit juice increased the area under the concentration versus time curve (4218+/-1497 ng x hr/ml [grapefruit juice] vs. 3415+/-1288 ng x hr/ml [water], P=0.029) and 12-hr trough (244+/-214 ng x ml [grapefruit juice] vs. 132+/-56 ng x ml [water], P=0.09), but it did not change peak concentration (734+/-290 ng x ml [grapefruit juice] vs. 708+/-305 ng x ml [water], P=0.76). In addition, grapefruit juice delayed the time to peak concentration compared with water (5.4+/-3.0 hr [grapefruit juice] vs. 2.8+/-0.8 hr [water], P=0.025). These data suggest that concurrent administration of grapefruit juice with CsA will delay the absorption of CsA and increase the drug exposure of CsA without changing peak concentration.
Asunto(s)
Citrus , Ciclosporina/farmacocinética , Adulto , Anciano , Bebidas , Disponibilidad Biológica , Citocromo P-450 CYP3A , Sistema Enzimático del Citocromo P-450/metabolismo , Femenino , Humanos , Trasplante de Riñón , Masculino , Persona de Mediana Edad , Oxigenasas de Función Mixta/metabolismoRESUMEN
Overall, patient and renal allograft survivals after cadaveric transplantation have improved significantly since the incorporation of CsA into the standard immunosuppressive regimen. Overall, patient and renal allograft survivals were significantly better for non-diabetic recipients when compared to diabetic recipients after cadaveric transplantation. Living-donor renal transplant recipients have a better outcome than cadaveric transplant recipients. Cardiovascular disease is the leading cause of death after renal transplantation. Death on dialysis accounted for the second largest number of posttransplant mortalities. Sepsis and malignancy remained the next most important causes of death after renal transplantation.
Asunto(s)
Trasplante de Riñón , Centros Médicos Académicos , Adolescente , Adulto , Anciano , Cadáver , Causas de Muerte , Niño , Preescolar , Nefropatías Diabéticas/mortalidad , Nefropatías Diabéticas/cirugía , Femenino , Supervivencia de Injerto , Humanos , Lactante , Recién Nacido , Iowa , Trasplante de Riñón/mortalidad , Trasplante de Riñón/tendencias , Donadores Vivos , Masculino , Persona de Mediana Edad , Tasa de Supervivencia , Factores de Tiempo , Donantes de TejidosAsunto(s)
Trasplante de Médula Ósea/inmunología , Trasplante Heterólogo/inmunología , Irradiación Corporal Total , Animales , Quimera , Ensayo de Unidades Formadoras de Colonias , Criopreservación , Rayos gamma , Humanos , Terapia de Inmunosupresión/métodos , Prueba de Cultivo Mixto de Linfocitos , Linfocitos/citología , Linfocitos/efectos de la radiación , PapioRESUMEN
Graft-versus-host disease (GVHD) remains a major complication of bone marrow transplantation. This report describes reversal of GVHD by infusion of stored recipient bone marrow following combined liver-bone marrow allotransplantation. Graft-versus-host disease developed at the end of the first postoperative week. The skin involvement progressively spread to approximately 80% of the body surface and was not affected by modification of the immunosuppressive treatment. On the 42nd and 43rd postoperative day 1.23 x 10(8) and 1.6 x 10(8) autologous bone marrow cells per kg of recipient body weight were infused. The skin rush began to dramatically improve and resolved within 2 wk from the autologous marrow infusion. Autologous bone marrow storage previous to allogeneic bone marrow transplantation for tolerance induction could constitute a safety net in case of occurrence of GVHD.